TTrialPathMatch Me to Trials
← Back to trials
RecruitingMajor Depressive Disorder (MDD)

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Eligible age

18–70 yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Sponsor: Supernus Pharmaceuticals, Inc.

You may qualify if…

  • ✓ Current diagnosis of MDD according to the DSM-5 for either single or recurrent MDE without psychotic features confirmed by the MINI
  • ✓ Duration of current MDE of at least 8 weeks
  • ✓ MADRS total score of ≥ 24 at the Screening Visit and Day 1 Visit
  • ✓ CGI-S score of ≥ 4 (moderately ill or worse) at the Screening Visit and Day 1 Visit
  • ✓ Stable, therapeutic dose of one of the following protocol-approved ADTs as a monotherapy for ≥ 8 weeks before the Screening Visit and ≥ 10 weeks at the Day 1 Visit. Additionally, inadequate response to the current ADT (less than 50% improvement in depressive symptoms) as confirmed by the ATRQ Investigator administered.

You may not qualify if…

  • ✕ MADRS total score change of ≥ 25% from the Screening Visit to Day 1 Visit
  • ✕ History of treatment resistant depression (TRD) defined as 3 or more failed ADTs of adequate dose (per ATRQ) and duration (at least 8 weeks) for the current MDE
  • ✕ History of alcohol or substance use disorder according to DSM-5 criteria 6 months before the Screening Visit
  • ✕ Evidence of significant risk for suicidal behavior during participation in the study in the Investigator's opinion
  • ✕ Lifetime diagnosis of any psychotic disorder including MDD with psychosis, MDD with mixed features, bipolar I/II disorder, bipolar depression, schizophrenia, posttraumatic stress disorder, autism spectrum disorder, or any personality disorder or intellectual disability that would affect the ability of the participant to enroll in the study
  • ✕ Diagnosis less then 12 months before screening of severe obsessive-compulsive disorder, acute stress disorder, panic disorder, eating disorders, or any other psychiatric condition that has been the primary focus of treatment, or diagnosis of generalized anxiety disorder less then 6 months before screening.
  • ✕ History of cardiovascular, respiratory, gastrointestinal, renal, hepatic, and hematologic disorders, or other medical disorders that could impose undue risk or compromise the study in the Investigator's opinion
  • ✕ Clinically significant abnormal result prior to Day 1 Visit per Investigator's judgment or abnormal renal function.

Where it's recruiting

Alabama

Birmingham

Arizona

Phoenix

Arkansas

Rogers

California

Chino · Encino · Garden Grove · Lemon Grove …

Colorado

Denver

Connecticut

Cromwell

Florida

Jacksonville · Miami · Orlando · Palm Bay …

Georgia

Atlanta · Decatur

Illinois

Warrenville

Missouri

O'Fallon · Saint Charles

Nevada

Las Vegas

Source: ClinicalTrials.gov · NCT07226661 · last updated 2026-11-16

Double-blind, Placebo-controlled Study in Adults With Major Depressive · TrialPath